-two articles published in this peer-reviewed scientific journal-
BELLEVILLE, ON, July 17 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the results of two large-scale commercial beef feedlot studies with the Company's Escherichia coli (E. coli) O157 vaccine - Econiche(TM) - have been published in this month's issue of Foodborne Pathogens and Disease (Vol. 6, Number 7, 2009), a peer-reviewed scientific journal.
The article, entitled, "A Randomized Longitudinal Trial to Test the Effect of Regional Vaccination Within a Cattle Feedyard on Escherichia coli O157:H7 Rectal Colonization, Fecal Shedding, and Hide Contamination", was co-authored by David R. Smith, Rodney A. Moxley, Terry J. Klopfenstein, and Galen E. Erickson.
This article summarized a large-scale clinical vaccine trial of commercially fed cattle in 2005 that tested the efficacy of vaccinating all cattle in within the feedyard using a two-dose regimen of Econiche. 504 cattle were randomly assigned to 63 pens within three treatment regions of the feedyard. One group received two doses of vaccine (ALLVAC); a second group received two doses of adjuvant as placebo (NOVAC); and in a third group, half received two doses of vaccine, while the other half received adjuvant (HALFVAC). Fecal shedding of E. coli O157:H7 was measured at 42, 63, and 84 days post-vaccination. Hide contamination was measured 42, 63, and 84 days post-vaccination at the feedyard, then on day 85 at the abattoir (meat processor). Colonization of the terminal rectal mucosa was also measured on day 85 at the abattoir.
For fecal shedding, regional vaccine efficacy of the ALLVAC group compared to the NOVAC pens was 63% (OR=0.34, p=0.0009), similar to vaccine efficacy of 52% for vaccinated cattle compared to placebo-treated cattle within HALFVAC pens (OR=0.48, p=0.014). For hide contamination,
'/>"/>
| SOURCE Bioniche Life Sciences Inc. Copyright©2009 PR Newswire. All rights reserved |